| Comprehensive analysis of hypermutation in human cancer BB Campbell, N Light, D Fabrizio, M Zatzman, F Fuligni, R de Borja, ... Cell 171 (5), 1042-1056. e10, 2017 | 691 | 2017 |
| First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE … HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ... The Lancet Oncology 18 (9), 1159-1171, 2017 | 370 | 2017 |
| Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma SJ Chatterjee, R Datar, D Youssefzadeh, B George, PJ Goebell, JP Stein, ... Journal of clinical oncology 22 (6), 1007-1013, 2004 | 322 | 2004 |
| Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers AD Singhi, B George, JR Greenbowe, J Chung, J Suh, A Maitra, ... Gastroenterology 156 (8), 2242-2253. e4, 2019 | 266 | 2019 |
| Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study M Javle, MJ Borad, NS Azad, R Kurzrock, GK Abou-Alfa, B George, ... The lancet oncology 22 (9), 1290-1300, 2021 | 240 | 2021 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 219 | 2022 |
| Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? KK Christians, S Tsai, A Mahmoud, P Ritch, JP Thomas, L Wiebe, T Kelly, ... The oncologist 19 (3), 266-274, 2014 | 212 | 2014 |
| Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer S Tsai, B George, D Wittmann, PS Ritch, AN Krepline, M Aldakkak, ... Annals of surgery 271 (4), 740-747, 2020 | 162 | 2020 |
| p53 Gene and Protein Status: The Role of p53 Alterations in Predicting Outcome in Patients With Bladder Cancer B George, RH Datar, L Wu, J Cai, N Patten, SJ Beil, S Groshen, J Stein, ... Journal of Clinical Oncology 25 (34), 5352-5358, 2007 | 150 | 2007 |
| Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy KK Christians, JW Heimler, B George, PS Ritch, BA Erickson, F Johnston, ... Surgery 159 (3), 893-900, 2016 | 127 | 2016 |
| Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer SJ Chatterjee, B George, PJ Goebell, M Alavi‐Tafreshi, SR Shi, YK Fung, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2004 | 113 | 2004 |
| Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease M Hwang, TT Jayakrishnan, DE Green, B George, JP Thomas, ... European journal of cancer 50 (10), 1747-1757, 2014 | 112 | 2014 |
| Arterial resection at the time of pancreatectomy for cancer KK Christians, CHC Pilgrim, S Tsai, P Ritch, B George, B Erickson, P Tolat, ... Surgery 155 (5), 919-926, 2014 | 108 | 2014 |
| Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer ZA Wainberg, HS Hochster, EJ Kim, B George, A Kaylan, EG Chiorean, ... Clinical cancer research 26 (18), 4814-4822, 2020 | 98 | 2020 |
| Non-metastatic pancreatic cancer: resectable, borderline resectable, and locally advanced-definitions of increasing importance for the optimal delivery of multimodality therapy DB Evans, B George, S Tsai Annals of Surgical Oncology 22, 3409-3413, 2015 | 98 | 2015 |
| Predictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI)–analysis of somatic alterations (SAs) AK Singavi, S Menon, D Kilari, A Alqwasmi, PS Ritch, JP Thomas, ... Annals of Oncology 28, v405, 2017 | 95 | 2017 |
| Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors JM Conroy, S Pabla, MK Nesline, ST Glenn, A Papanicolau-Sengos, ... Journal for immunotherapy of cancer 7, 1-11, 2019 | 93 | 2019 |
| Chemotherapy for surgically resected intrahepatic cholangiocarcinoma JT Miura, FM Johnston, S Tsai, B George, J Thomas, D Eastwood, ... Annals of surgical oncology 22, 3716-3723, 2015 | 93 | 2015 |
| Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients S Pabla, JM Conroy, MK Nesline, ST Glenn, A Papanicolau-Sengos, ... Journal for immunotherapy of cancer 7, 1-13, 2019 | 84 | 2019 |
| The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer AP Mitra, AA Almal, B George, DW Fry, PF Lenehan, V Pagliarulo, ... BMC cancer 6, 1-16, 2006 | 84 | 2006 |
